Aaron Ellenbogen

Donanemab in Early Symptomatic Alzheimer Disease

John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text

Medicine, Neurology, Neuroscience +17

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Joseph Jankovic, Ira Goodman, Beth Safirstein et al. · JAMA Neurology · 2018 · 292 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry et al. · Science Translational Medicine · 2022 · 252 citations

Life Sciences, Neuroscience, Pharmacology +17

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Laura Fanning, Serena Hung, Aaron Ellenbogen et al. · Movement Disorders · 2019 · 194 citations · Full text

Life Sciences, Neurology, Pharmacology +17

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer et al. · The Lancet Neurology · 2021 · 117 citations

Medicine, Pharmacology, Pharmacotherapy +14